Document Detail


Does parathyroid hormone affect erythropoietin therapy in dialysis patients?
MedLine Citation:
PMID:  17159367     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The objective of this study was to assess the response to recombinant human erythropoietin (rHuEPO) during treatment of anemia in dialysis patients with hyperparathyroidism. SUBJECTS AND METHODS: A total of 118 patients with stage 5 renal failure on dialysis therapy were selected for this study. Anemia was treated with rHuEPO. Laboratory data for each patient included intact parathyroid hormone (iPTH), hemoglobin (Hb), hematocrit (Hct), blood urea nitrogen, serum creatinine, calcium, phosphate, and alkaline phosphatase. Patients with iPTH >32 pmol/l were considered hyperparathyroid. Erythropoietin resistance index (ERI) was expressed as the ratio of weekly rHuEPO dose/Hct level. RESULTS: Of the 118 patients, 83 (70.3%) were on hemodialysis (HD) and 35 (29.7%) were on continuous ambulatory peritoneal dialysis (CAPD). Sixty-three patients (64.3%) with iPTH >32 pmol/l had Hb <11 g/dl, while 34 (54.8%) with iPTH <32 had Hb >11 g/dl (p = 04). Thirty-three (56%) patients with iPTH >32 pmol/l had hemocrit <33%, while 38 (61.3%) with iPTH <32 had hemocrit <33% (p = 0.4). The median value of weekly rHuEPO dose in HD patients (12,000 units) was significantly higher in comparison with CAPD patients (6,000 units; p < 0.0001). ERI was significantly higher in HD than CAPD patients with iPTH <16 pmol/l (p = 0002) as well as with patients with 16-32 pmol/l (p = 0.012). CONCLUSIONS: CAPD patients showed a reduced requirement for rHuEPO and better control of anemia compared with HD patients. ERI was also lower in CAPD than in HD patients. Hyperparathyroidism is a parameter predictive of rHuEPO hyporesponsiveness in dialysis patients.
Authors:
Nabieh Al-Hilali; Hani Al-Humoud; Vadakethu T Ninan; Mangalathillam R N Nampoory; Mini A Puliyclil; Kaivilayil V Johny
Related Documents :
10430967 - Indices of activity of the nitric oxide system in hemodialysis patients.
21654057 - Erythrocyte aggregation in patients with systemic lupus erythematosus.
8557807 - Visual attention and perception in patients with huntington's disease: comparisons with...
8474487 - Assessment of adaptive functioning in huntington's disease.
22423667 - High false negative rate of tc-99m mdp whole-body bone scintigraphy in detecting skelet...
16702447 - Review of the abdominal manifestations of cystic fibrosis in the adult patient.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Medical principles and practice : international journal of the Kuwait University, Health Science Centre     Volume:  16     ISSN:  1011-7571     ISO Abbreviation:  Med Princ Pract     Publication Date:  2007  
Date Detail:
Created Date:  2006-12-12     Completed Date:  2007-02-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8901334     Medline TA:  Med Princ Pract     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  63-7     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2007 S. Karger AG, Basel.
Affiliation:
Department of Medicine, Mubarak Al-Kabeer Hospital, Kuwait.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Anemia / drug therapy*
Erythropoietin / therapeutic use*
Female
Humans
Hyperparathyroidism*
Male
Middle Aged
Parathyroid Hormone / blood
Peritoneal Dialysis, Continuous Ambulatory*
Renal Dialysis*
Chemical
Reg. No./Substance:
0/Parathyroid Hormone; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Occurrence of Campylobacter jejuni in Shiraz, Southwest Iran.
Next Document:  Hydatid disease of the first rib causing thoracic outlet syndrome.